Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease

Louise Collins(University College Cork), André Toulouse(University College Cork), Thomas J. Connor(Trinity College Dublin), Yvonne M. Nolan(University College Cork)
Neuropharmacology
February 15, 2012
10.1016/j.neuropharm.2012.01.028
Cited by 296Open Access
Full Text

Abstract

Related Papers

Understanding cell death in parkinson's disease
Peter Jenner, C. Warren Olanow|Annals of Neurology|1998|692
Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition
Emilie Croisier, Linda Moran, David T. Dexter et al.|Journal of Neuroinflammation|2005|430
Regulatory T Cells Attenuate Th17 Cell-Mediated Nigrostriatal Dopaminergic Neurodegeneration in a Model of Parkinson’s Disease
Ashley D. Reynolds, David K. Stone, Jessica A. L. Hutter et al.|The Journal of Immunology|2010|405
Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with IκBα induction and block of NFκB and iNOS activation
Thomas Dehmer, Michael T. Heneka, Magdalena Sastre et al.|Journal of Neurochemistry|2003|381
Proinflammatory Effects of IL-10 During Human Endotoxemia
Fanny N. Lauw, Dasja Pajkrt, C. Erik Hack et al.|The Journal of Immunology|2000|325